Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma
Sign Up to like & getrecommendations! Published in 2024 at "Blood Cancer Journal"
DOI: 10.1038/s41408-024-01155-y
Abstract: Belantamab mafodotin is a fi rst-in-class humanized, afucosylated, anti-B-cell maturation antigen (BCMA) monoclonal antibody conjugated to the microtubule inhibitor monomethyl auristatin F [1]. Preclinical studies showed belantamab mafodotin interacts synergistically with standard-of-care agents for multiple… read more here.
Keywords: mafodotin; trial; phase dreamm; belantamab mafodotin ... See more keywords
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
Sign Up to like & getrecommendations! Published in 2025 at "Blood Cancer Journal"
DOI: 10.1038/s41408-025-01212-0
Abstract: Patients with relapsed/refractory multiple myeloma (RRMM) have a poor prognosis and a need remains for novel effective therapies. Belantamab mafodotin, an anti–B-cell maturation antigen antibody-drug conjugate, was granted accelerated/conditional approval for patients with RRMM who… read more here.
Keywords: dreamm; mafodotin; refractory multiple; belantamab mafodotin ... See more keywords
Safety and efficacy of depatuxizumab mafodotin monotherapy or in combination with temozolomide in patients with/without EGFR-amplified recurrent glioblastoma: a systematic review
Sign Up to like & getrecommendations! Published in 2025 at "Annals of Medicine and Surgery"
DOI: 10.1097/ms9.0000000000003869
Abstract: This study aimed to assess the safety and efficacy of depatuxizumab mafodotin as a monotherapy or in combination with temozolomide in patients with recurrent epidermal growth factor receptor (EGFR)-amplified glioblastoma multiforme, focusing on overall survival… read more here.
Keywords: mafodotin; combination; efficacy depatuxizumab; depatuxizumab mafodotin ... See more keywords
Belantamab mafodotin for relapsed or refractory multiple myeloma
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/10781552221086265
Abstract: Objective: Refractory multiple myeloma (MM) presents poor responses to therapies. New drugs for highly pretreated MM are a hope for this clinical context with limited treatment options. We developed a comparative commentary on the evidence… read more here.
Keywords: mafodotin; relapsed refractory; belantamab mafodotin; refractory multiple ... See more keywords